

Particulates present in dosage form of the invention
Dosage form of the invention
% w/w released
Time (hours)
0
10
20
30
40
50
60
70
80
90
100
0 2 4 6 8 10 12 14 16 18 20 22 24

Fig. 1



Release (%)
Time (Hr)
0
20
40
60
80
100
0 2 4 6 8 10 12 14 16 18
Example 3 (hydromorphone) (particulates) in SGF
Example 3 (naloxone) (particulates) in SGF
Example 2 (hydromorphone) (particulates) in 40% EtOH
Example 2 (naloxone) (particulates) in 40% EtOH
Example 3 (hydromorphone) (tablets) in SGF
Example 3 (naloxone) (tablets) in SGF
Example 3 (hydromorphone) (tablets) in 40% EtOH
Example 3 (naloxone) (tablets) in 40% EtOH

Fig. 2



Release (%)
Time (Hr)
Example 4 (hydromorphone) (tablets) in SGF
Example 4 (naloxone) (tablets) in SGF
Example 2 (hydromorphone) (particulates) in SGF
Example 2 (naloxone) (particulates) in SGF

Fig. 3



Release (%)
Time (Hr)
Example 5 (hydromorphone) (tablets) in SGF
Example 5 (naloxone) (tablets) in SGF
Example 2 (hydromorphone) (particulates) in SGF
Example 2 (naloxone) (particulates) in SGF

Fig. 4



Release (%)
Time (Hr)
Example 5 (hydromorphone) (tablets) in SGF
Example 5 (naloxone) (tablets) in SGF
Example 5 (hydromorphone) (tablets) in 40% EtOH
Example 5 (naloxone) (tablets) in 40% EtOH

Fig. 5



Release (%)
Time (Hr)
Example 7 (hydromorphone) (tablets) in SGF
Example 7 (naloxone) (tablets) in SGF
Example 6 (hydromorphone) (particulates) in SGF
Example 6 (naloxone) (particulates) in SGF

Fig. 6



Release (%)
100
80
60
40
20
0
0
2
4
6
8
10
12
14
16
18
Time (Hr)
Example 7 (hydromorphone) (tablets) in SGF
Example 7 (naloxone) (tablets) in SGF
Example 7 (hydromorphone) (tablets) in 40% EtOH
Example 7 (naloxone) (tablets) in 40% EtOH

Fig. 7




Fig. 8a




Fig. 8b




Fig. 9a



Fig. 9b




Fig. 10